No Prescription |
 |
 | ||
|
CIZA Suspension Propulsid |
|
| ||
No Prescription » Prescription Drugs 4 » CIZA Suspension Propulsid Category:Cholinergic enhancer Gastrointestinal emptying (delayed) adjunct. Cisapride increases the rate at which your esophagus stomach and intestines move during digestion. It also increases the rate at which your stomach empties into your intestines and increases the strength of your lower esophageal sphincter (the muscle between your stomach and your esophagus).Cisapride is used to treat gastric reflux (the regurgitation of stomach acid into the esophagus) which is usually experienced as heartburn.Cisapride (SIS-a-pride) is a medicine that increases the movements or contractions of the stomach and intestines. It is used to treat symptoms such as heartburn caused by a backward flow of stomach acid into the esophagus. Buy CIZA Suspension Propulsid and other Prescription Drugs 4 products online at Medstore. 2127
About CIZA Suspension Propulsid: Product Type: Prescription Drugs 4 CIZA Suspension - (Propulsid Generic Cisapride) CIZA Suspension - (Propulsid Generic Cisapride) Propulsid Generic Cisapride 1mg/ml syrup 180ml (3 x 60ml) Propulsid Generic Cisapride CIZA Suspension -
View more Prescription Drugs 4 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
